OTCPK:CYCA

Stock Analysis Report

Executive Summary

Cytta Corp. is engaged in the manufacture, distribution, and marketing of various telephony based Internet access and computing products and services in the eHealth industry.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • Cytta has significant price volatility in the past 3 months.
  • Cytta's last earnings update was 836 days ago.
  • Cytta is not covered by any analysts.

Share Price & News

How has Cytta's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

CYCA

0.9%

US Healthcare Services

-0.2%

US Market


1 Year Return

13.3%

CYCA

8.7%

US Healthcare Services

1.1%

US Market

CYCA outperformed the Healthcare Services industry which returned 8.6% over the past year.

CYCA outperformed the Market in United States of America which returned 1.6% over the past year.


Share holder returns

CYCAIndustryMarket
7 Day0%0.9%-0.2%
30 Day36.0%-5.2%2.5%
90 Day-11.2%-5.5%1.6%
1 Year13.3%13.3%8.8%8.7%3.4%1.1%
3 Year187.4%187.4%49.7%49.4%45.2%35.8%
5 Year-82.1%-82.1%50.3%49.4%62.6%44.8%

Price Volatility Vs. Market

How volatile is Cytta's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cytta undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Cytta is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Cytta has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Cytta's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Cytta regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Cytta expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cytta has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine Cytta's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Cytta's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Cytta performed over the past 5 years?

0.2%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Cytta has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Cytta's financial position?


In this section we usually analyse Cytta's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Cytta has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of CYCA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Cytta's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Cytta's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Cytta's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Cytta's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Cytta has not reported any payouts.

Unable to verify if Cytta's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Cytta has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Cytta's salary, the management and board of directors tenure and is there insider trading?

3.9yrs

Average management tenure


CEO

Gary Campbell (65yo)

9.3yrs

Tenure

US$180,000

Compensation

Mr. Gary Campbell, B.Comm., LL.B., serves as the Chief Executive Officer of Cytta Corp. since June 2010 and has been its Treasurer since November 15, 2010 and Secretary since March 12, 2010. Mr. Campbell s ...


Management Age and Tenure

3.9yrs

Average Tenure

The tenure for the Cytta management team is about average.


Board Age and Tenure

3.9yrs

Average Tenure

65yo

Average Age

The tenure for the Cytta board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Management Team

  • Gary Campbell (65yo)

    Chairman

    • Tenure: 9.3yrs
    • Compensation: US$180.00k
  • Erik Stephansen (55yo)

    President & Director

    • Tenure: 6.3yrs
    • Compensation: US$187.50k
  • Ted Fellerman

    Chief Investment Officer

    • Tenure: 3.9yrs
  • Daniel Jacoy

    Vice President of Finance & Business Strategy

    • Tenure: 2.6yrs
  • Michael Collins

    Chief Visionary Officer & Director of Digital Media

    • Tenure: 0yrs
  • Lee Skoblow

    Vice President of Investor Relations & Market Strategy

    • Tenure: 0yrs

Board Members

  • Bill Nance (75yo)

    Member of Board of Corporate Advisors

    • Tenure: 3.9yrs
  • Marilyn Harz

    Member of Board of Advisors

    • Tenure: 0yrs
  • Gary Campbell (65yo)

    Chairman

    • Tenure: 9.3yrs
    • Compensation: US$180.00k
  • Erik Stephansen (55yo)

    President & Director

    • Tenure: 6.3yrs
    • Compensation: US$187.50k
  • Natalia Sokolova

    Director

    • Tenure: 0yrs
  • Darren Pleasance

    Member of Board of Advisors

    • Tenure: 0yrs
  • Harvey Sussman

    Member of Board of Advisors

    • Tenure: 0yrs
  • Nicholas Donoghoe

    Member of Board of Medical Advisors

    • Tenure: 0yrs
  • Ross McCabe

    Member of Board of Medical Advisors

    • Tenure: 0yrs
  • David Mescher

    Member of Board of Medical Advisors

    • Tenure: 0yrs

Company Information

Cytta Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cytta Corp.
  • Ticker: CYCA
  • Exchange: OTCPK
  • Founded: 2006
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$6.309m
  • Shares outstanding: 185.55m
  • Website: https://www.cytta.com

Number of Employees


Location

  • Cytta Corp.
  • 6490 West Desert Inn Road
  • Las Vegas
  • Nevada
  • 89146
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CYCAOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDOct 2007

Biography

Cytta Corp. is engaged in the manufacture, distribution, and marketing of various telephony based Internet access and computing products and services in the eHealth industry. The company delivers health an ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 00:49
End of Day Share Price2019/09/16 00:00
Earnings2014/06/30
Annual Earnings2013/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.